From the Department of Radiology, University of Pamukkale, Denizli, Turkey.
Department of Pulmonology, University of Pamukkale, Denizli, Turkey.
J Comput Assist Tomogr. 2024;48(3):415-423. doi: 10.1097/RCT.0000000000001577. Epub 2024 Jan 9.
The aims of this study were to assess the chest computed tomography (CT) findings in post-COVID-19 respiratory condition (rPCC) patients and compare the findings with asymptomatic participants (APs). It also aimed to evaluate the relationship between CT findings and pulmonary function tests (PFTs) in rPCC patients. Finally, it aimed to compare the quantitative chest CT findings and PFT results of patients with rPCC and APs.
We retrospectively enrolled consecutive patients with rPCC who underwent unenhanced chest CT and PFTs between June 2020 and September 2022. In addition, a control group (APs) was prospectively formed and underwent nonenhanced chest CT and PFTs. The presence and extent of abnormalities in unenhanced chest CT images were evaluated qualitatively and semiquantitatively in a blinded manner. We used fully automatic software for automatic lung and airway segmentation and quantitative analyses.
Sixty-three patients with rPCC and 23 APs were investigated. Reticulation/interstitial thickening and extent of parenchymal abnormalities on CT were significantly greater in the rPCC group than in the control group ( P = 0.001 and P = 0.004, respectively). Computed tomography extent score was significantly related to length of hospital stay, age, and intensive care unit stay (all P s ≤ 0.006). The rPCC group also had a lower 85th percentile attenuation lung volume ( P = 0.037). The extent of parenchymal abnormalities was significantly correlated with carbon monoxide diffusing capacity ( r = -0.406, P = 0.001), forced vital capacity (FVC) ( r = -0.342, P = 0.002), and forced expiratory volume in 1 second/FVC ( r = 0.427, P < 0.001) values. Pulmonary function tests revealed significantly lower carbon monoxide diffusing capacity ( P < 0.001), FVC ( P = 0.036), and total lung capacity ( P < 0.001) values in the rPCC group.
The rPCC is characterized by impaired PFTs, a greater extent of lung abnormalities on CT, and decreased 85th percentile attenuation lung volume. Advanced age, intensive care unit admission history, and extended hospital stay are risk factors for chest CT abnormalities.
本研究旨在评估 COVID-19 后呼吸系统疾病(rPCC)患者的胸部计算机断层扫描(CT)表现,并将其与无症状参与者(APs)进行比较。还旨在评估 rPCC 患者 CT 表现与肺功能测试(PFTs)之间的关系。最后,比较 rPCC 患者和 APs 的定量胸部 CT 表现和 PFT 结果。
我们回顾性纳入了 2020 年 6 月至 2022 年 9 月期间接受增强胸部 CT 和 PFTs 的连续 rPCC 患者。此外,还前瞻性地形成了对照组(APs),并进行了非增强胸部 CT 和 PFTs。使用全自动软件进行自动肺和气道分割和定量分析,以盲法评估非增强胸部 CT 图像中的异常存在和程度。
共纳入了 63 例 rPCC 患者和 23 例 APs。rPCC 组 CT 上的网状/间质增厚和实质异常程度明显大于对照组(P=0.001 和 P=0.004)。CT 范围评分与住院时间、年龄和重症监护病房入住时间显著相关(均 P 值≤0.006)。rPCC 组的 85%衰减肺容积也较低(P=0.037)。实质异常程度与一氧化碳弥散量(r=-0.406,P=0.001)、用力肺活量(FVC)(r=-0.342,P=0.002)和 1 秒用力呼气量/FVC(r=0.427,P<0.001)显著相关。rPCC 组的肺一氧化碳弥散量(P<0.001)、FVC(P=0.036)和总肺容量(P<0.001)明显降低。
rPCC 的特点是 PFTs 受损、CT 上的肺部异常程度更大和 85%衰减肺容积降低。高龄、入住重症监护病房和住院时间延长是胸部 CT 异常的危险因素。